Quick Answer
Can-Fite BioPharma Ltd. reported Diluted EPS of $5.97 per share (loss) for fiscal year 2025.
Can-Fite BioPharma Ltd. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$5.97 | +45.0% |
| 2024 | -$10.86 | +39.4% |
| 2023 | -$17.92 | -179100.0% |
| 2022 | -$0.01 | +66.7% |
| 2021 | -$0.03 | +25.0% |
| 2020 | -$0.04 | — |
- Can-Fite BioPharma Ltd. showed an increase of +45.0% in Diluted EPS compared to the prior fiscal year.
- Over the 2020–2025 period, Can-Fite BioPharma Ltd.’s diluted eps has declined by 14825.0% (from $0.04 per share (loss) to $5.97 per share (loss)).
- The most recent figure is from Can-Fite BioPharma Ltd.’s fiscal year 2025 report (Form 20-F), filed with the SEC on March 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: